ror2 (Santa Cruz Biotechnology)
Santa Cruz Biotechnology is a verified supplier 
93
Structured Review
Santa Cruz Biotechnology
ror2
Ror2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 60 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ror2/pmc12634580-10-0-4?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 60 article reviews
Ror2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 60 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ror2/pmc12634580-10-0-4?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 60 article reviews
ror2 - by Bioz Stars,
2026-07
93/100 stars
Images
1) Product Images from "Astrocytic Ror2-induced imbalance in brain and gut homeostasis contributes to chronic post-thoracotomy pain"
Article Title: Astrocytic Ror2-induced imbalance in brain and gut homeostasis contributes to chronic post-thoracotomy pain
Journal: Frontiers in Aging Neuroscience
doi: 10.3389/fnagi.2025.1675725
Figure Legend Snippet: Upregulated levels of Ror2, CCL2, and CXCL1 in the ACC during CPTP. (A,C,E) Western blot analysis of Ror2, CCL2, and CXCL1 protein levels in the sham and CPTP groups on POD 7, 14, and 21. (B,D,F) Western blot analysis of Ror2, CCL2, and CXCL1 protein levels on POD 21. (G,I,K) Quantitative analysis of Ror2, CCL2, or CXCL1 co-localization with GFAP on POD 21. (H,J,L) On POD 21, immunofluorescence analysis showed the co-localization of Ror2, CCL2, and CXCL1 (all red) with GFAP (green). Scale bar: 50 μm; ### P < 0.001 compared with the non-CPTP group; ** P < 0.01, and *** P < 0.001 compared with the sham group; one-way ANOVA; n = 3 per group.
Techniques Used: Western Blot, Immunofluorescence
Figure Legend Snippet: Astrocytic Ror2 knockdown mitigated pain behaviors associated with thoracotomy. (A) Design overview of the experiment. Intrathecal injection of AAV2/9-GFAP-miR30-shRor2 (40 μL) and AAV2/9-GFAP-Control (40 μL) 21 days before thoracotomy. Pain behavioral testing, western blotting, immunofluorescence, and SCFAs measurement were conducted at specified intervals. (B) The incidence rates of CPTP and non-CPTP were compared between the AAV2/9-GFAP-miR30-shRor2 and AAV2/9-GFAP-Control groups on POD 21. # P < 0.05, ## P < 0.01, and ### P < 0.001 compared with the AAV2/9-GFAP-Control-non-CPTP group; * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with the AAV2/9-GFAP-Control-CPTP group; using chi-square test. (C) Evaluation of mechanical hyperalgesia in CPTP and non-CPTP rats following intrathecal injection of AAV2/9-GFAP-miR30-shRor2. (D) Evaluation of cold allodynia by scratching behaviors following intrathecal AAV2/9-GFAP-miR30-shRor2 injection. (E) MWT histogram on POD 21 for all groups. (F) Scratching behavior histogram for all groups on POD 21. * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with the AAV2/9-GFAP-Control-CPTP group; # P < 0.05, ## P < 0.01, and ### P < 0.001 compared with the AAV2/9-GFAP-Control-non-CPTP group; △ P < 0.05, △△ P < 0.01, △△△ P < 0.001 compared with the AAV2/9-GFAP-Control-sham; two-way ANOVA; group sizes: both AAV2/9-GFAP-miR30-shRor2-sham and AAV2/9-GFAP-Control-sham ( n = 10), AAV2/9-GFAP-Control-non-CPTP ( n = 12), AAV2/9-GFAP-Control-CPTP ( n = 18), AAV2/9-GFAP-miR30-shRor2-non-CPTP ( n = 27), and AAV2/9-GFAP-miR30-shRor2-CPTP ( n = 3).
Techniques Used: Knockdown, Injection, Control, Western Blot, Immunofluorescence
Figure Legend Snippet: Astrocytic Ror2 knockdown rebalanced the A1/A2 ratio in the ACC in CPTP rats. (A,B) Western blotting analysis of C3 and S100A10 after spinal delivery of AAV2/9-GFAP-miR30-shRor2 or AAV2/9-GFAP-Control in CPTP rats. (C,D) Quantitative co-localization analysis of C3 or S100A10 with GFAP in the AAV2/9-GFAP-miR30-shRor2-CPTP group compared with the AAV2/9-GFAP-Control-CPTP group (POD 21), n = 3 per group. ** P < 0.01, and *** P < 0.001 compared with the AAV2/9-GFAP-Control-CPTP group; one-way ANOVA; n = 3 per group. (E,F) Immunofluorescence staining revealed co-localization of C3 or S100A10 (all red) with GFAP (green) in the AAV2/9-GFAP-miR30-shRor2-CPTP group on POD 7, 14, and 21 compared with the AAV2/9-GFAP-Control-CPTP group on POD 21; n = 3 per group.
Techniques Used: Knockdown, Western Blot, Control, Immunofluorescence, Staining
Figure Legend Snippet: Astrocytic Ror2 knockdown downregulated CCL2 and CXCL1 in the ACC in CPTP rats. (A,B,C) Western blotting of Ror2, CCL2, and CXCL1 levels on POD 7, 14, and 21. *** P < 0.001 compared with the AAV2/9-GFAP-Control-CPTP group (POD 21); one-way ANOVA; n = 3 per group.
Techniques Used: Knockdown, Western Blot, Control